Finkelstein Thompson LLP Announces Investigation of IDM Pharma, Inc.

WASHINGTON, May 20, 2009 (GLOBE NEWSWIRE) – Legal Newswire Service – Finkelstein Thompson LLP
is investigating potential shareholder claims arising from the proposed
acquisition of IDM Pharma, Inc. (“IDM” or the “Company”) (Nasdaq:IDMI)
by Takeda Pharmaceutical Co. Under the terms of the merger agreement,
IDM shareholders will receive $2.64 per share, valuing the transaction
at approximately $66.7 million.

The investigation is focused on the potential unfairness of the merger
price and of the process by which the IDM Board of Directors approved
the agreement.

If you are interested in discussing your rights as an IDM shareholder,
or have information relating to this investigation, please contact
Finkelstein Thompson’s Washington, DC offices at (877) 337-1050 or by
email at

Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients in
connection with securities and other finance-related litigation, and
has been appointed as lead or co-lead counsel in dozens of shareholder
class actions. Indeed, the firm has served in leadership roles in cases
that have recovered over $1 billion for investors and consumers. To
learn more about Finkelstein Thompson LLP, please visit our web site at

Scroll to Top